Immuron Ltd (ASX: IMC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Immuron Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $20.29 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 227.80 million
Earnings per share -0.017
Dividend per share N/A
Year To Date Return 15.58%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Immuron Ltd (ASX: IMC)
    Latest News

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Share Gainers

    Guess which ASX healthcare stock is rocketing 97% on big FDA news

    ASX investor are sending the healthcare stock soaring on Thursday.

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Healthcare Shares

    Why the Immuron (ASX:IMC) share price rocketed another 17% today

    The biotech company is experiencing another healthy share jump today.

    Read more »

    a man raises his fists to the air in joyous celebration while learning some exciting good news via his computer screen in an office setting.
    Healthcare Shares

    Here's why the Immuron (ASX:IMC) share price is rocketing 31% today

    The company's shares are one of the best performers on the ASX today.

    Read more »

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Healthcare Shares

    Immuron (ASX:IMC) share price surges 11% on COVID-19 treatment data

    New research suggests the company's drug might be able to treat COVID-19

    Read more »

    A woman kicks a giant COVID-19 molecule, indicating positive share price movement for biotech companies
    Healthcare Shares

    Why the Immuron (ASX:IMC) share price is surging 8% higher

    The Immuron Ltd (ASX: IMC) share price is surging 8% today after providing an update on its drug candidate, IMM124E.…

    Read more »

    woman in lab coat conducting testing representing biotech
    Share Market News

    Why the Immuron (ASX:IMC) share price fell today

    The Immuron (ASX:IMC) share price closed lower today following the company's recently released earnings report. Here's the run down.

    Read more »

    A happy businessman pointing up, inidicating a rise in share price
    Share Market News

    Why the Immuron (ASX:IMC) share price is rocketing up 10% today

    The Immuron Limited (ASX: IMC) share price is surging today following a research agreement with Monash University for combating COVID-19.

    Read more »

    Young girl wearing a suit and tie with rocket wings looks to the sky representing the highest traded stocks today
    Share Market News

    Why the Immuron (ASX:IMC) share price is rocketing 18% higher today

    The Immuron share price is soaring higher today, up 18% in afternoon trading. We take a look at the company's…

    Read more »

    Share Market News

    Afterpay and Immuron were among the most traded shares on the ASX last week

    Afterpay Ltd (ASX:APT) and Openpay Group Ltd (ASX:OPY) shares were among the most traded shares on the ASX last week. Here's…

    Read more »

    Share Market News

    Immuron share price falls 27% on registered direct offering

    Immuron share price falls 27% following the announcement of its registered direct offering. We take a look at the intricacies…

    Read more »

    Chalk-drawn rocket shown blasting off into space
    Share Market News

    Immuron share price shoots 90% higher on potential COVID-19 treatment news

    The Immuron Limited (ASX: IMC) share price has shot 90% higher today following a release regarding the effect of its…

    Read more »

    Green dollar sign rocket on the back of a man.
    Share Market News

    Immuron share price shoots 6% higher after receiving FDA guidance for new drug

    The Immuron Limited (ASX: IMC) share price shot up 6% today after receiving guidance for its new oral therapeutic. We…

    Read more »

    IMC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Immuron Ltd

    Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

    IMC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    14 Jun 2024 $0.09 $0.00 0.00% 48,955 $0.09 $0.09 $0.09
    13 Jun 2024 $0.09 $0.00 0.00% 162,417 $0.09 $0.09 $0.09
    11 Jun 2024 $0.09 $0.00 0.00% 139,108 $0.09 $0.09 $0.09
    07 Jun 2024 $0.09 $0.00 0.00% 15,657 $0.09 $0.09 $0.09
    06 Jun 2024 $0.09 $0.00 0.00% 78,000 $0.09 $0.09 $0.09
    04 Jun 2024 $0.09 $0.00 0.00% 7,600 $0.09 $0.09 $0.09
    03 Jun 2024 $0.09 $0.00 0.00% 87,937 $0.10 $0.10 $0.09
    31 May 2024 $0.09 $0.00 0.00% 140,149 $0.09 $0.09 $0.09
    30 May 2024 $0.10 $0.00 0.00% 135,527 $0.10 $0.10 $0.09
    29 May 2024 $0.10 $0.00 0.00% 74,648 $0.09 $0.10 $0.09
    28 May 2024 $0.09 $0.00 0.00% 72,512 $0.09 $0.09 $0.09
    27 May 2024 $0.09 $0.00 0.00% 191,667 $0.09 $0.09 $0.09
    24 May 2024 $0.09 $0.00 0.00% 332,285 $0.09 $0.09 $0.09
    23 May 2024 $0.09 $0.00 0.00% 147,437 $0.09 $0.09 $0.09
    22 May 2024 $0.09 $0.00 0.00% 64,466 $0.09 $0.09 $0.09
    21 May 2024 $0.09 $0.00 0.00% 120,000 $0.09 $0.09 $0.09
    20 May 2024 $0.09 $0.00 0.00% 17,378 $0.09 $0.09 $0.09
    17 May 2024 $0.09 $0.00 0.00% 337,740 $0.09 $0.09 $0.09
    16 May 2024 $0.09 $0.00 0.00% 500,480 $0.09 $0.09 $0.09

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    31 May 2024 Roger Aston Transfer 144,000 $13,536
    Off-market transfer. Assuming off market transfer of shares
    31 May 2024 Roger Aston Transfer 144,000 $13,536
    Off-market transfer. Assuming off market transfer of shares
    12 Mar 2024 Daniel Pollock Buy 200,000 $24,000
    Exercise of options.
    12 Mar 2024 Daniel Pollock Exercise 200,000 $24,000
    Exercise of options.
    08 Mar 2024 Daniel Pollock Sell 200,000 $31,400
    On-market trade.
    24 Nov 2023 Paul Brennan Issued 1,000,000 $76,000
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Paul Brennan Non-Executive DirectorNon-Executive Chairman Mar 2022
    Mr Brennan has experience in the health system through his clinical background and commercial exposure with various multinational companies. Mr Brennan was Chief Executive Officer(CEO) of PolyNovo Limited (ASX:PNV) for seven years from 2015 to 2021. Prior to this Mr Brennan was Marketing Director Australia and New Zealand and Sales Director New Zealand for Smith & Nephew Healthcare for six years.
    Mr Daniel Pollock Non-Executive Director Oct 2012
    Mr Pollock is a sole practitioner in his own legal firm based in Melbourne which operates internationally and specializes in commercial law. Further, he is executive director and co-owner of Great Accommodation Pty Ltd, a property management business operating in Victoria. Mr. Pollock has had involvement as a seed investor and board member of a number of small unlisted companies. The most recent of these was an e-pharmacy company where he was heavily involved in its commercial growth and ultimate sale to a large listed health services company. He also has special responsibilities as chair of the risk committee and a member of the remuneration committee.
    Mr Ravi Savarirayan Non-Executive Director Apr 2017
    Mr Savarirayan has been a consultant clinical geneticist at the Victorian Clinical Genetics Services since August 1999, as well as professor and research group leader of Molecular therapies at the Murdoch Children's Research Institute since September 2000. Prof. Savarirayan has served as a founding member of the Skeletal Dysplasia Management Consortium since January 2011 and has acted as the chair of the specialist advisory committee in clinical genetics at the Royal Australasian College of Physicians since February 2009. He was president of the International Skeletal Dysplasia Society from July 2009 to June 2011 and has been an invited member of several international working committees on constitutional diseases of bone. Prof. Savarirayan's primary research focus is on inherited disorders of the skeleton causing short stature, arthritis and osteoporosis. He has published over 210 peer-reviewed articles, collaborating with peers from over 30 countries. He has been on the editorial board of Human Mutation since January 2009, European Journal of Human Genetics since July 2007, American Journal of Medical Genetics since December 2011 and the Journal of Medical Genetics since June 2005. He is an NHMRC Leadership fellow.
    Dr Jeannette Joughin Non-Executive Director Jun 2024
    Dr Joughin has senior executive/operational roles with Bristol Myers Squibb, CSL, CCRM Australia and the OneVentures portfolio companies including BiVACOR, Hatchtech and ImmVirX.
    Mr Phillip Hains Chief Financial OfficerCompany Secretary Apr 2013
    -
    Mr Steven Lydeamore Chief Executive Officer Jun 2022
    -
    Flavio Palumbo Chief Commercial Officer
    -
    Jerry Kanellos Chief Operating Officer
    -
    Steven Lydeamore Chief Executive Officer
    -
    Phillip Hains Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 78,973,505 34.67%
    Authentics Australia Pty Ltd <Authentics Australia A/C> 6,000,000 2.63%
    Grandlodge Pty Ltd 3,846,712 1.69%
    Dr Russell Kay Hancock 3,000,000 1.32%
    Citicorp Nominees Pty Limited 2,560,458 1.12%
    Karma Wealth Pty Ltd <Lally Family Super Fund A/C> 2,551,665 1.12%
    Mr Stephen Anastasiou & Mrs Andria Anastasiou <Anastasiou Family S/F A/C> 2,494,746 1.10%
    Texas Woods Pty Ltd <The Plush Family A/C> 2,314,674 1.02%
    Gravcon Pty Ltd 2,000,000 0.88%
    Insync Investments Pty Ltd <Weekley Super Fund No 1 A/C> 2,000,000 0.88%
    Mr William David Frank Bird 1,500,000 0.66%
    Hallam Drainage Pty Ltd <Brian Corrigan Superfund A/C> 1,480,064 0.65%
    Mr Iain Chaney & Mrs Antonia Chaney <I & A Chaney Super Fund> 1,408,288 0.62%
    Dr Roger Aston 1,371,376 0.60%
    Mr Anthony Frederick Wallace Hyett 1,350,000 0.59%
    Anne Pattison Pty Ltd <Aep No 3 A/C> 1,345,000 0.59%
    Mr Peter Anastasiou & Mrs Kristine Patricia Anastasiou <Anastasiou Super Fund A/C> 1,332,187 0.59%
    Mr Lizhong Yu 1,300,000 0.57%
    South Bay Nominees Pty Ltd <C & P Hong Family A/C> 1,300,000 0.57%
    Vkm Holdings Pty Ltd <Taltressa Super Fund A/C> 1,300,000 0.57%

    Profile

    since

    Note